Amaravathi Cancer Treatment Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.77 Cr
as on 16-11-2024
- Company Age 6 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.40 Cr
as on 16-11-2024
- Satisfied Charges ₹ 5.00 Cr
as on 16-11-2024
- Revenue 15.99%
(FY 2023)
- Profit 66.22%
(FY 2023)
- Ebitda 11.36%
(FY 2023)
- Net Worth 73.34%
(FY 2023)
- Total Assets -4.85%
(FY 2023)
About Amaravathi Cancer Treatment
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.77 Cr.
The company currently has active open charges totaling ₹6.40 Cr. The company has closed loans amounting to ₹5.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vikranth Mummaneni, Rajesh Kota, and Ramu Kandula serve as directors at the Company.
- CIN/LLPIN
U85200AP2018PTC108346
- Company No.
108346
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 May 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Krishna, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Amaravathi Cancer Treatment?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikranth Mummaneni  | Director | 07-May-2018 | Current |
| Rajesh Kota | Director | 07-May-2018 | Current |
| Ramu Kandula | Director | 07-May-2018 | Current |
Financial Performance of Amaravathi Cancer Treatment.
Amaravathi Cancer Treatment Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 15.99% increase. The company also saw a substantial improvement in profitability, with a 66.22% increase in profit. The company's net worth Soared by an impressive increase of 73.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Amaravathi Cancer Treatment?
In 2023, Amaravathi Cancer Treatment had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pravira Health Enterprises Private LimitedActive 5 years 2 monthsVikranth Mummaneni and Rajesh Kota are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 19 Jun 2024 | ₹2.79 Cr | Open |
Axis Bank Limited Creation Date: 18 Nov 2021 | ₹3.61 Cr | Open |
Others Creation Date: 03 Jul 2019 | ₹5.00 Cr | Satisfied |
How Many Employees Work at Amaravathi Cancer Treatment?
Unlock and access historical data on people associated with Amaravathi Cancer Treatment, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Amaravathi Cancer Treatment, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Amaravathi Cancer Treatment's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
